Pharma & Biotech Mergers & Acquisitions News
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
Belgium-headquartered SERB Specialty Pharmaceuticals has made its first acquisition in the UK, thus substantially increasing its presence in this market. 20 May 2020
Pharmaceutical
US firms Neurotrope and Metuchen Pharmaceuticals are to merge in an all-stock transaction resulting in a newly-formed holding company to be renamed Petros Pharmaceuticals. 18 May 2020
Biotechnology
Boehringer Ingelheim has acquired Northern Biologics, a wholly-owned subsidiary of Canada-based Northern LP, the German family-owned pharma major announced today. 14 May 2020
Pharmaceutical
In what appeared to be a surprise for both analysts and the company itself, Japan’s Takeda Pharmaceutical cleared 100 billion yen ($934 million) in operating profit last fiscal year, notwithstanding the impact of its outsized acquisition activity. 13 May 2020
Pharmaceutical
Italy’s Menarini kicked off the May M&A news last week, announcing it would acquire USA-based Stemline Therapeutics, gaining access to an already approved drug for rare blood cancer, Elzonris. This was followed by Alexion agreeing a $1.41 billion takeover offer for Portola Pharmaceuticals, along with its clotting factor Andexxa. Meantime, US health technology assessor, the Institute for Clinical and Economic Review (ICER), has come up with two scenarios on fair pricing for COVID-19 treatment remdesivir from Gilead Sciences. On the regulatory front, the US Food and Drug Administration granted earlier-than-expected approval for Novartis and Incyte’s new lung cancer drug Tabrecta (capmatinib). 10 May 2020
Biotechnology
Privately-held Italian pharma group Mediolanum Farmaceutici has acquired the French immuno-oncology specialist ElsaLys Biotech. 7 May 2020
Biotechnology
In another strategic M&A deal announced so far this month, PTC Therapeutics has entered into an agreement to acquire fellow USA-based rare metabolic disease drug developer Censa Pharmaceuticals. 7 May 2020
Biotechnology
Following a couple of active M&A years, USA-based Alexion Pharmaceuticals has now reached a definitive agreement to acquire Portola Pharmaceuticals, a commercial-stage biotech focused on blood-related disorders. 6 May 2020
Pharmaceutical
Almost a year after the original announcement, the US Federal Trade Commission (FTC) has accepted the proposed consent order in connection with AbbVie's pending $63 billion acquisition of Ireland-incorporated Allergan. 6 May 2020
Biotechnology
Privately-held pharma and diagnostics firm Menarini Group has announced a definitive agreement to acquire USA-based Stemline Therapeutics. 5 May 2020
Pharmaceutical
In its first quarterly results statement of the year, New York-based pharma giant Pfizer revealed net income of $3.4 billion, better than analysts had expected, based on revenues of $12 billion. 28 April 2020
Generics
European regulators have approved the merger of Pfizer’s generics division, Upjohn, with Netherlands-headquartered generics company Mylan. 23 April 2020
Pharmaceutical
Astellas Pharma today revealed that it has acquired Nanna Therapeutics, a UK biotech company focused on addressing age-related diseases with high unmet medical need including mitochondria-related diseases. 21 April 2020
Pharmaceutical
Swiss pharma giant Novartis says it has completed the acquisition of Amblyotech, a USA-based software start-up. 20 April 2020
Pharmaceutical
Hopes that Gilead Sciences’ antiviral remdesivir could soon be approved to treat people with COVID-19 have been dealt a blow by a trial stoppage. 16 April 2020
Biotechnology
Two new cancer companies, PIC Therapeutics and Amphista Therapeutics, have been launched by Advent Life Sciences. 15 April 2020
Biotechnology
Daiichi Sankyo has commenced an open innovation research program relating to a gene therapy for restoring vision with Mitsubishi UFJ Capital and the Nagoya Institute of Technology (NITech). 14 April 2020
Biotechnology
Privately-held, clinical-stage US biotech company Tarveda Therapeutics says that the proposed merger agreement with Organovo Holdings has been terminated following the emergence of unanticipated, late opposition to the proposed transaction by major Organovo stockholders. 8 April 2020
Pharmaceutical
There has quietly been a significant series of pharma industry acquisitions during the month of March, even if much of the public focus on the sector is currently on its efforts fighting COVID-19. 6 April 2020
Biotechnology
Independent drugmaker Servier has agreed to buy the antibody discovery company Symphogen. 3 April 2020
Biotechnology
AlloVir has entered into a definitive agreement to merge with biopharma company Kalaris Therapeutics. 8 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Biotechnology
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Biotechnology
German drugmaker Dr Falk Pharma GmbH today announced completion of the acquisition of Kynos Therapeutics, a clinical stage biopharmaceutical company focusing on the development of novel KMO inhibitors for acute and chronic inflammatory diseases. 29 October 2024
Biotechnology
US Pharma major AbbVie has reached a definitive agreement to acquire Aliada Therapeutics, a biotech advancing therapies using a novel blood-brain barrier (BBB)-crossing technology to address challenging central nervous system (CNS) diseases. 29 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Biotechnology
California, USA-based Lyell Immunopharma (Nasdaq: LYEL) has entered into a definitive agreement to acquire privately-held US CAR-T company ImmPACT Bio. 26 October 2024
Biotechnology
Mumbai-based Mankind Pharma has completed its acquisition of Bharat Serums and Vaccines (BSV), adding to its portfolio in the women’s health and fertility market. 24 October 2024
Biotechnology
Ocuphire Pharma has announced its acquisition of Opus Genetics, a clinical-stage gene therapy company focused on treating inherited retinal diseases. 24 October 2024
Biotechnology
Connecticut, USA-based Modifi Biosciences today announced that the company has been acquired by pharma giant Merck & Co 23 October 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Pharmaceutical
Last week’s significant news included Denmark-based CNS drugmaker Lundbeck reaching agreement to acquire US firm Longboard Pharmaceuticals, along with its bexicaserin, for $2.6 billion. Also, US pharma giant Pfizer entered into a deal with TRIANA Biomedicines to develop molecular glue degraders. On the regulatory front, the US Food and Drug Administration (FDA) last week approved Novocure’s key product Optune Lua for lung cancer patients. Also, German biotech BioNTech and its US partner OncoC4 received a partial clinical hold from the FDA on the Phase III trial of gotistobart in lung cancer. The European Medicines Agency’s human health committee, CHMP, Reaffirmed its non-approval of PTC Therapeutic’s Translarna. 20 October 2024
Biotechnology
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge. 18 October 2024
Biotechnology
Danish CNS specialist Lundbeck today revealed that it has reached to acquire Longboard Pharmaceuticals. 15 October 2024
Biotechnology
USA-based Kezar Life Sciences announced this week that it was pausing its Phase IIb PALIZADE trial evaluating zetomipzomib in lupus nephritis (LN) following the deaths of four patients. 10 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze